RxDoctor Payments Data

Narayan Verma, MD

Neurology · Warren, MINPI 1083680235

Payments from drug & device makers

$21,480in general payments, 2019–2025

Across 561 payments — averaging $38.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13K
  • Livanova USA, Inc.$2K
  • Novartis$2K
  • Teva Pharmaceuticals USA, Inc.$756
  • Biogen$749
  • Supernus Pharmaceuticals, Inc.$589
  • plus $4K from 37 others

What the payments were for

  • Speaking & faculty fees$9,81346%
  • Travel & lodging$2,15010%
  • Food & beverage$8,83541%
  • Education$6823%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,480 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$158,218
Medicare patients
260
Services billed
2,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab30$253,628
IngrezzaValbenazine Tosylate16$128,620
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5018$110,585
EpidiolexCannabidiol (Cbd)14$105,651
OctagamImmun Globg(Igg)/Malt/Iga Ov5012$99,641
Plegridy PenPeginterferon Beta-1a12$94,467
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$88,015
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5014$60,724
Dalfampridine ErDalfampridine32$33,626
Nurtec OdtRimegepant Sulfate15$31,865
RexultiBrexpiprazole14$19,285
VraylarCariprazine Hcl14$18,028
Aimovig AutoinjectorErenumab-Aooe19$13,403
FycompaPerampanel13$12,145
Depakote ErDivalproex Sodium11$11,354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Nurtec Odt, Dilantin$158$134,06639 claims
Otsuka America Pharmaceutical, Inc.Rexulti$57$19,28514 claims
AbbVieVraylar$12,626$18,02814 claims
Eisai Inc.Fycompa$232$12,14513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 652 neurology providers in Michigan.

Other neurology in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →